Armistice Capital Master Fund Ltd. - Net Worth and Insider Trading

Armistice Capital Master Fund Ltd. Net Worth

The estimated net worth of Armistice Capital Master Fund Ltd. is at least $215 Million dollars as of 2024-12-26. Armistice Capital Master Fund Ltd. is the 10% Owner of Del Frisco′s Restaurant Group Inc and owns about 12,650,000 shares of Del Frisco′s Restaurant Group Inc (DFRG) stock worth over $101 Million. Armistice Capital Master Fund Ltd. is the 10% Owner of AMAG Pharmaceuticals Inc and owns about 4,468,000 shares of AMAG Pharmaceuticals Inc (AMAG) stock worth over $61 Million. Armistice Capital Master Fund Ltd. is also the 10% Owner of Reshape Lifesciences Inc and owns about 10,660,554 shares of Reshape Lifesciences Inc (RSLS) stock worth over $29 Million. Besides these, Armistice Capital Master Fund Ltd. also holds Innovus Pharmaceuticals Inc (INNV) , Alimera Sciences Inc (ALIM) , Cassava Sciences Inc (SAVA) , Achieve Life Sciences Inc (ACHV) , Aytu BioPharma Inc (AYTU) , Cyclo Therapeutics Inc (CYTH) , Vaxart Inc (VXRT) , Traws Pharma Inc (TRAW) , Avalo Therapeutics Inc (AVTX) , Bio-Path Holdings Inc (BPTH) , Tenax Therapeutics Inc (TENX) , Fresh Tracks Therapeutics Inc (FRTX) , Kiora Pharmaceuticals Inc (KPRX) , Valeritas Holdings Inc (VLRXQ) . Details can be seen in Armistice Capital Master Fund Ltd.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Armistice Capital Master Fund Ltd. has not made any transactions after 2023-06-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Armistice Capital Master Fund Ltd.

Armistice Capital Master Fund Ltd. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Armistice Capital Master Fund Ltd. owns 20 companies in total, including Cyclo Therapeutics Inc (CYTH) , Reshape Lifesciences Inc (RSLS) , and Tenax Therapeutics Inc (TENX) among others .

Click here to see the complete history of Armistice Capital Master Fund Ltd.’s form 4 insider trades.

Insider Ownership Summary of Armistice Capital Master Fund Ltd.

Ticker	Comapny	Transaction Date	Type of Owner
CYTH	Cyclo Therapeutics Inc	2020-09-30	10 percent owner
RSLS	Reshape Lifesciences Inc	2020-12-04	10 percent owner
TENX	Tenax Therapeutics Inc	2021-07-08	director
		2023-06-27	director & 10 percent owner
		2020-07-28	director & 10 percent owner
		2020-06-29	10 percent owner
		2020-12-11	10 percent owner
		2020-03-16	10 percent owner
		2020-02-14	10 percent owner
		2021-08-02	director & 10 percent owner
		2019-12-20	10 percent owner
		2019-09-25	10 percent owner
		2019-09-23	10 percent owner
		2019-06-11	10 percent owner
		2019-01-18	10 percent owner
		2019-01-10	10 percent owner
		2018-10-03	10 percent owner
		2018-09-20	10 percent owner
		2018-02-06	10 percent owner
		2017-03-21	10 percent owner

Armistice Capital Master Fund Ltd. Latest Holdings Summary

Armistice Capital Master Fund Ltd. currently owns a total of 17 stocks. Among these stocks, Armistice Capital Master Fund Ltd. owns 12,650,000 shares of Del Frisco′s Restaurant Group Inc (DFRG) as of June 4, 2019, with a value of $101 Million and a weighting of 47.04%. Armistice Capital Master Fund Ltd. owns 4,468,000 shares of AMAG Pharmaceuticals Inc (AMAG) as of March 16, 2020, with a value of $61 Million and a weighting of 28.63%. Armistice Capital Master Fund Ltd. also owns 10,660,554 shares of Reshape Lifesciences Inc (RSLS) as of December 4, 2020, with a value of $29 Million and a weighting of 13.71%. The other 14 stocks Innovus Pharmaceuticals Inc (INNV) , Alimera Sciences Inc (ALIM) , Cassava Sciences Inc (SAVA) , Achieve Life Sciences Inc (ACHV) , Aytu BioPharma Inc (AYTU) , Cyclo Therapeutics Inc (CYTH) , Vaxart Inc (VXRT) , Traws Pharma Inc (TRAW) , Avalo Therapeutics Inc (AVTX) , Bio-Path Holdings Inc (BPTH) , Tenax Therapeutics Inc (TENX) , Fresh Tracks Therapeutics Inc (FRTX) , Kiora Pharmaceuticals Inc (KPRX) , Valeritas Holdings Inc (VLRXQ) have a combined weighting of 10.62% among all his current holdings.

Latest Holdings of Armistice Capital Master Fund Ltd.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
DFRG	Del Frisco′s Restaurant Group Inc	2019-06-04	12,650,000	7.98	100,947,000
AMAG	AMAG Pharmaceuticals Inc	2020-03-16	4,468,000	13.75	61,435,000
RSLS	Reshape Lifesciences Inc	2020-12-04	10,660,554	2.76	29,423,129
INNV	Innovus Pharmaceuticals Inc	2019-09-17	600,000	20.82	12,492,000
ALIM	Alimera Sciences Inc	2018-02-06	924,805	5.54	5,123,420
SAVA	Cassava Sciences Inc	2018-10-03	1,651,340	2.54	4,186,147
ACHV	Achieve Life Sciences Inc	2019-06-11	79,659	3.78	301,111
AYTU	Aytu BioPharma Inc	2020-12-11	133,333	1.50	200,000
CYTH	Cyclo Therapeutics Inc	2020-09-30	315,915	0.57	180,166
VXRT	Vaxart Inc	2020-06-29	291,046	0.61	176,083
TRAW	Traws Pharma Inc	2019-09-23	4,356	10.92	47,568
AVTX	Avalo Therapeutics Inc	2023-06-27	3,191	9.06	28,910
BPTH	Bio-Path Holdings Inc	2019-01-18	12,930	1.34	17,326
TENX	Tenax Therapeutics Inc	2020-09-08	2,525	5.65	14,274
FRTX	Fresh Tracks Therapeutics Inc	2019-01-10	13,778	0.75	10,265
KPRX	Kiora Pharmaceuticals Inc	2021-08-02	2,181	3.35	7,295
VLRXQ	Valeritas Holdings Inc	2019-12-20	0	0.02	0

Holding Weightings of Armistice Capital Master Fund Ltd.

Armistice Capital Master Fund Ltd. Form 4 Trading Tracker

According to the SEC Form 4 filings, Armistice Capital Master Fund Ltd. has made a total of 0 transactions in Del Frisco′s Restaurant Group Inc (DFRG) over the past 5 years. The most-recent trade in Del Frisco′s Restaurant Group Inc is the acquisition of 25,000 shares on June 4, 2019, which cost Armistice Capital Master Fund Ltd. around $149,000.

According to the SEC Form 4 filings, Armistice Capital Master Fund Ltd. has made a total of 5 transactions in AMAG Pharmaceuticals Inc (AMAG) over the past 5 years, including 4 buys and 1 sells. The most-recent trade in AMAG Pharmaceuticals Inc is the acquisition of 24,000 shares on March 16, 2020, which cost Armistice Capital Master Fund Ltd. around $116,880.

According to the SEC Form 4 filings, Armistice Capital Master Fund Ltd. has made a total of 10 transactions in Reshape Lifesciences Inc (RSLS) over the past 5 years, including 10 buys and 0 sells. The most-recent trade in Reshape Lifesciences Inc is the acquisition of 6,400 shares on December 4, 2020, which cost Armistice Capital Master Fund Ltd. around $26,624.

More details on Armistice Capital Master Fund Ltd.'s insider transactions can be found in the Insider Trading History of Armistice Capital Master Fund Ltd. table.

Insider Trading History of Armistice Capital Master Fund Ltd.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Armistice Capital Master Fund Ltd. Trading Performance

GuruFocus tracks the stock performance after each of Armistice Capital Master Fund Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Armistice Capital Master Fund Ltd. is 19.97%. GuruFocus also compares Armistice Capital Master Fund Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Armistice Capital Master Fund Ltd. within 3 months outperforms 80 times out of 159 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Armistice Capital Master Fund Ltd.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Armistice Capital Master Fund Ltd.

Average Return

Average return per transaction

Outperforming Transactions

44 out of 129 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	4.1
Relative Return to S&P 500(%)	2.53

Armistice Capital Master Fund Ltd. Ownership Network

Ownership Network List of Armistice Capital Master Fund Ltd.

No Data

Ownership Network Relation of Armistice Capital Master Fund Ltd.

Armistice Capital Master Fund Ltd. Owned Company Details

What does Cyclo Therapeutics Inc do?

Who are the key executives at Cyclo Therapeutics Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Cyclo Therapeutics Inc. Other key executives at Cyclo Therapeutics Inc include 10 percent owner Rafael Holdings, Inc. , director & Chief Executive Officer Jeffrey Tate , and SVP for Medical Affairs Sharon Hemond Hrynkow .

Cyclo Therapeutics Inc (CYTH) Insider Trades Summary

Over the past 18 months, Armistice Capital Master Fund Ltd. made no insider transaction in Cyclo Therapeutics Inc (CYTH). Other recent insider transactions involving Cyclo Therapeutics Inc (CYTH) include a net purchase of 4,000,000 shares made by Rafael Holdings, Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Cyclo Therapeutics Inc (CYTH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cyclo Therapeutics Inc (CYTH) were sold and 4,000,000 shares were bought by its insiders, resulting in a net purchase of 4,000,000 shares.

Cyclo Therapeutics Inc (CYTH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cyclo Therapeutics Inc Insider Transactions

No Available Data

What does Reshape Lifesciences Inc do?

Who are the key executives at Reshape Lifesciences Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Reshape Lifesciences Inc. Other key executives at Reshape Lifesciences Inc include Chief Financial Officer Thomas Stankovich , President and CEO Barton P. Bandy , and director & Chairman & President and CEO Dan W Gladney .

Reshape Lifesciences Inc (RSLS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Reshape Lifesciences Inc (RSLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Reshape Lifesciences Inc (RSLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Reshape Lifesciences Inc (RSLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Reshape Lifesciences Inc Insider Transactions

No Available Data

What does Tenax Therapeutics Inc do?

Who are the key executives at Tenax Therapeutics Inc?

Armistice Capital Master Fund Ltd. is the director of Tenax Therapeutics Inc. Other key executives at Tenax Therapeutics Inc include Interim CFO Eliot M Lurier , director & CEO Chrisopher Thomas Giordano , and Chief Medical Officer Stuart Rich .

Tenax Therapeutics Inc (TENX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Tenax Therapeutics Inc (TENX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Tenax Therapeutics Inc (TENX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Tenax Therapeutics Inc (TENX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tenax Therapeutics Inc Insider Transactions

No Available Data

What does Avalo Therapeutics Inc do?

Who are the key executives at Avalo Therapeutics Inc?

Armistice Capital Master Fund Ltd. is the director & 10 percent owner of Avalo Therapeutics Inc. Other key executives at Avalo Therapeutics Inc include 10 percent owner Caissa Capital Management Ltd. , Interim CFO Christopher Ryan Sullivan , and Chief Medical Officer Garry Arthur Neil .

Avalo Therapeutics Inc (AVTX) Insider Trades Summary

Over the past 18 months, Armistice Capital Master Fund Ltd. made 1 insider transaction in Avalo Therapeutics Inc (AVTX) with a net sale of 3,683,542. Other recent insider transactions involving Avalo Therapeutics Inc (AVTX) include a net purchase of 1,000 shares made by June Sherie Almenoff ,

In summary, during the past 3 months, insiders sold 0 shares of Avalo Therapeutics Inc (AVTX) in total and bought 1,000 shares, with a net purchase of 1,000 shares. During the past 18 months, 15,348 shares of Avalo Therapeutics Inc (AVTX) were sold and 1,000 shares were bought by its insiders, resulting in a net sale of 14,348 shares.

Avalo Therapeutics Inc (AVTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avalo Therapeutics Inc Insider Transactions

No Available Data

What does Tetraphase Pharmaceuticals Inc do?

Who are the key executives at Tetraphase Pharmaceuticals Inc?

Armistice Capital Master Fund Ltd. is the director & 10 percent owner of Tetraphase Pharmaceuticals Inc. Other key executives at Tetraphase Pharmaceuticals Inc include director & See Remarks Larry G. Edwards , director & 10 percent owner Steven Boyd , and director & 10 percent owner Armistice Capital, Llc .

Tetraphase Pharmaceuticals Inc (TTPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Tetraphase Pharmaceuticals Inc (TTPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Tetraphase Pharmaceuticals Inc (TTPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Tetraphase Pharmaceuticals Inc (TTPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tetraphase Pharmaceuticals Inc Insider Transactions

No Available Data

What does Vaxart Inc do?

Who are the key executives at Vaxart Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Vaxart Inc. Other key executives at Vaxart Inc include Chief Financial Officer Phillip E Lee , Interim CFO Fuad Ahmad , and SVP & General Counsel Edward B Berg .

Vaxart Inc (VXRT) Insider Trades Summary

Over the past 18 months, Armistice Capital Master Fund Ltd. made no insider transaction in Vaxart Inc (VXRT). Other recent insider transactions involving Vaxart Inc (VXRT) include a net purchase of 20,000 shares made by W. Mark Watson ,

In summary, during the past 3 months, insiders sold 0 shares of Vaxart Inc (VXRT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vaxart Inc (VXRT) were sold and 20,000 shares were bought by its insiders, resulting in a net purchase of 20,000 shares.

Vaxart Inc (VXRT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vaxart Inc Insider Transactions

No Available Data

What does Aytu BioPharma Inc do?

Who are the key executives at Aytu BioPharma Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Aytu BioPharma Inc. Other key executives at Aytu BioPharma Inc include Chief Financial Officer Mark K Oki , Chief Operating Officer Christopher Brooke , and Chief Business Officer Jarrett Disbrow .

Aytu BioPharma Inc (AYTU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aytu BioPharma Inc (AYTU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aytu BioPharma Inc (AYTU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aytu BioPharma Inc (AYTU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aytu BioPharma Inc Insider Transactions

No Available Data

What does AMAG Pharmaceuticals Inc do?

Who are the key executives at AMAG Pharmaceuticals Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of AMAG Pharmaceuticals Inc. Other key executives at AMAG Pharmaceuticals Inc include 10 percent owner Camber Capital Management Lp , Chief Operating Officer Anthony Casciano , and Interim CFO Brian Piekos .

AMAG Pharmaceuticals Inc (AMAG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AMAG Pharmaceuticals Inc (AMAG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AMAG Pharmaceuticals Inc (AMAG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AMAG Pharmaceuticals Inc (AMAG)'s detailed insider trading history can be found in Insider Trading Tracker table.

AMAG Pharmaceuticals Inc Insider Transactions

No Available Data

What does Innovus Pharmaceuticals Inc do?

Who are the key executives at Innovus Pharmaceuticals Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Innovus Pharmaceuticals Inc. Other key executives at Innovus Pharmaceuticals Inc include 10 percent owner Armistice Capital, Llc , 10 percent owner Steven Boyd , and EVP & CORPORATE DEVELOPMENT Randy Berholtz .

Innovus Pharmaceuticals Inc (INNV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Innovus Pharmaceuticals Inc (INNV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Innovus Pharmaceuticals Inc (INNV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Innovus Pharmaceuticals Inc (INNV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Innovus Pharmaceuticals Inc Insider Transactions

No Available Data

What does Kiora Pharmaceuticals Inc do?

Who are the key executives at Kiora Pharmaceuticals Inc?

Armistice Capital Master Fund Ltd. is the director & 10 percent owner of Kiora Pharmaceuticals Inc. Other key executives at Kiora Pharmaceuticals Inc include EVP of Finance Melissa Tosca , Chief Development Officer Eric Joseph Daniels , and director & President and CEO Brian M. Strem .

Kiora Pharmaceuticals Inc (KPRX) Insider Trades Summary

Over the past 18 months, Armistice Capital Master Fund Ltd. made no insider transaction in Kiora Pharmaceuticals Inc (KPRX). Other recent insider transactions involving Kiora Pharmaceuticals Inc (KPRX) include a net purchase of 2,100 shares made by Melissa Tosca , a net purchase of 5,260 shares made by Erin Parsons , and a net purchase of 5,000 shares made by Praveen Tyle .

In summary, during the past 3 months, insiders sold 0 shares of Kiora Pharmaceuticals Inc (KPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kiora Pharmaceuticals Inc (KPRX) were sold and 22,291 shares were bought by its insiders, resulting in a net purchase of 22,291 shares.

Kiora Pharmaceuticals Inc (KPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kiora Pharmaceuticals Inc Insider Transactions

No Available Data

What does Valeritas Holdings Inc do?

Who are the key executives at Valeritas Holdings Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Valeritas Holdings Inc. Other key executives at Valeritas Holdings Inc include 10 percent owner Armistice Capital, Llc , 10 percent owner Steven Boyd , and 10 percent owner Cr Group L.p. .

Valeritas Holdings Inc (VLRXQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Valeritas Holdings Inc (VLRXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Valeritas Holdings Inc (VLRXQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Valeritas Holdings Inc (VLRXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Valeritas Holdings Inc Insider Transactions

No Available Data

What does Del Frisco′s Restaurant Group Inc do?

Who are the key executives at Del Frisco′s Restaurant Group Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Del Frisco′s Restaurant Group Inc. Other key executives at Del Frisco′s Restaurant Group Inc include 10 percent owner Armistice Capital, Llc , 10 percent owner Steven Boyd , and President & Grille Coleman Brandon Charles Iii .

Del Frisco′s Restaurant Group Inc (DFRG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Del Frisco′s Restaurant Group Inc (DFRG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Del Frisco′s Restaurant Group Inc (DFRG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Del Frisco′s Restaurant Group Inc (DFRG)'s detailed insider trading history can be found in Insider Trading Tracker table.

Del Frisco′s Restaurant Group Inc Insider Transactions

No Available Data

What does Traws Pharma Inc do?

Who are the key executives at Traws Pharma Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Traws Pharma Inc. Other key executives at Traws Pharma Inc include CHIEF MEDICAL OFFICER Victor M Moyo , VP Corp Dev & Gen Counsel Abraham N. Oler , and Chief Medical Officer Steven M Fruchtman .

Traws Pharma Inc (TRAW) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Traws Pharma Inc (TRAW) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Traws Pharma Inc (TRAW) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Traws Pharma Inc (TRAW)'s detailed insider trading history can be found in Insider Trading Tracker table.

Traws Pharma Inc Insider Transactions

No Available Data

What does Achieve Life Sciences Inc do?

Who are the key executives at Achieve Life Sciences Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Achieve Life Sciences Inc. Other key executives at Achieve Life Sciences Inc include CFO and PFO John Bencich , director & President & CEO Richard Alistair Stewart , and 10 percent owner Dialectic Life Sciences Spv Llc .

Achieve Life Sciences Inc (ACHV) Insider Trades Summary

Over the past 18 months, Armistice Capital Master Fund Ltd. made no insider transaction in Achieve Life Sciences Inc (ACHV). Other recent insider transactions involving Achieve Life Sciences Inc (ACHV) include a net purchase of 10,000 shares made by John Bencich , and a net purchase of 10,000 shares made by Richard Alistair Stewart .

In summary, during the past 3 months, insiders sold 0 shares of Achieve Life Sciences Inc (ACHV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achieve Life Sciences Inc (ACHV) were sold and 20,000 shares were bought by its insiders, resulting in a net purchase of 20,000 shares.

Achieve Life Sciences Inc (ACHV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achieve Life Sciences Inc Insider Transactions

No Available Data

What does Bio-Path Holdings Inc do?

Who are the key executives at Bio-Path Holdings Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Bio-Path Holdings Inc. Other key executives at Bio-Path Holdings Inc include director & President & CEO & CFO Peter Henry Nielsen , 10 percent owner Armistice Capital, Llc , and 10 percent owner Steven Boyd .

Bio-Path Holdings Inc (BPTH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Bio-Path Holdings Inc (BPTH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Bio-Path Holdings Inc (BPTH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Bio-Path Holdings Inc (BPTH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bio-Path Holdings Inc Insider Transactions

No Available Data

What does Fresh Tracks Therapeutics Inc do?

Who are the key executives at Fresh Tracks Therapeutics Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Fresh Tracks Therapeutics Inc. Other key executives at Fresh Tracks Therapeutics Inc include Chief Medical Officer Monica E. Luchi , director & CHAIRMAN OF THE BOARD Reginald L Hardy , and General Counsel and CCO David R. Mcavoy .

Fresh Tracks Therapeutics Inc (FRTX) Insider Trades Summary

Over the past 18 months, Armistice Capital Master Fund Ltd. made no insider transaction in Fresh Tracks Therapeutics Inc (FRTX). Other recent insider transactions involving Fresh Tracks Therapeutics Inc (FRTX) include a net sale of 110 shares made by ,

In summary, during the past 3 months, insiders sold 0 shares of Fresh Tracks Therapeutics Inc (FRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 110 shares of Fresh Tracks Therapeutics Inc (FRTX) were sold and 1,086,412 shares were bought by its insiders, resulting in a net purchase of 1,086,302 shares.

Fresh Tracks Therapeutics Inc (FRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fresh Tracks Therapeutics Inc Insider Transactions

No Available Data

What does Cassava Sciences Inc do?

Who are the key executives at Cassava Sciences Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Cassava Sciences Inc. Other key executives at Cassava Sciences Inc include Chief Financial Officer Eric Schoen , Chief Clinical Dev. Officer James William Kupiec , and SVP & General Counsel Robert Christopher Cook .

Cassava Sciences Inc (SAVA) Insider Trades Summary

Over the past 18 months, Armistice Capital Master Fund Ltd. made no insider transaction in Cassava Sciences Inc (SAVA). Other recent insider transactions involving Cassava Sciences Inc (SAVA) include a net sale of 61,800 shares made by Eric Schoen , a net purchase of 30,000 shares made by Sanford Robertson , and a net purchase of 18,477 shares made by Richard Barry .

In summary, during the past 3 months, insiders sold 65,800 shares of Cassava Sciences Inc (SAVA) in total and bought 0 shares, with a net sale of 65,800 shares. During the past 18 months, 65,800 shares of Cassava Sciences Inc (SAVA) were sold and 48,477 shares were bought by its insiders, resulting in a net sale of 17,323 shares.

Cassava Sciences Inc (SAVA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cassava Sciences Inc Insider Transactions

No Available Data

What does Seelos Therapeutics Inc do?

Who are the key executives at Seelos Therapeutics Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Seelos Therapeutics Inc. Other key executives at Seelos Therapeutics Inc include director & See Remarks Raj Mehra , Chief Financial Officer Michael Joseph Golembiewski , and SVP & Chief Business Officer Neil Morton .

Seelos Therapeutics Inc (SEELQ) Insider Trades Summary

Over the past 18 months, Armistice Capital Master Fund Ltd. made no insider transaction in Seelos Therapeutics Inc (SEELQ). Other recent insider transactions involving Seelos Therapeutics Inc (SEELQ) include a net purchase of 83,000 shares made by Michael Joseph Golembiewski , and a net purchase of 75,757 shares made by Raj Mehra .

In summary, during the past 3 months, insiders sold 0 shares of Seelos Therapeutics Inc (SEELQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Seelos Therapeutics Inc (SEELQ) were sold and 1,240 shares were bought by its insiders, resulting in a net purchase of 1,240 shares.

Seelos Therapeutics Inc (SEELQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Seelos Therapeutics Inc Insider Transactions

No Available Data

What does Alimera Sciences Inc do?

Who are the key executives at Alimera Sciences Inc?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Alimera Sciences Inc. Other key executives at Alimera Sciences Inc include 10 percent owner Caligan Partners Lp , 10 percent owner David Edward Johnson , and other: Chairman Emeritus C. Daniel Myers .

Alimera Sciences Inc (ALIM) Insider Trades Summary

Over the past 18 months, Armistice Capital Master Fund Ltd. made no insider transaction in Alimera Sciences Inc (ALIM). Other recent insider transactions involving Alimera Sciences Inc (ALIM) include a net sale of 0 shares made by Caligan Partners Lp ,

In summary, during the past 3 months, insiders sold 0 shares of Alimera Sciences Inc (ALIM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 579,000 shares of Alimera Sciences Inc (ALIM) were sold and 579,000 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alimera Sciences Inc (ALIM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alimera Sciences Inc Insider Transactions

No Available Data

What does Dynatronics Corp do?

Who are the key executives at Dynatronics Corp?

Armistice Capital Master Fund Ltd. is the 10 percent owner of Dynatronics Corp. Other key executives at Dynatronics Corp include Chief Financial Officer Gabriel Ellwein , director & Chief Executive Officer John Anthony Krier , and Chief Operating Officer Brian D. Baker .

Dynatronics Corp (DYNT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dynatronics Corp (DYNT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dynatronics Corp (DYNT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dynatronics Corp (DYNT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dynatronics Corp Insider Transactions

No Available Data

Armistice Capital Master Fund Ltd. Mailing Address

Above is the net worth, insider trading, and ownership report for Armistice Capital Master Fund Ltd.. You might contact Armistice Capital Master Fund Ltd. via mailing address: C/o Armistice Capital, Llc, 510 Madison Avenue, 7th Floor, New York Ny 10022.

Discussions on Armistice Capital Master Fund Ltd.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.